lectin/neoplasms

CROSS-REFERENCES TO RELATED APPLICATION This patent application claims the benefit of priority from Korean Patent Application No. 10-2012-0031277, filed on Mar. 27, 2012, the contents of which are incorporated herein by reference. REFERENCE TO A SEQUENCE LISTING This application contains a Sequence

REFERENCE TO SEQUENCE LISTING SUBMITTED VIA EFS-WEB The entire content of the following electronic submission of the sequence listing via the USPTO EFS-WEB server, as authorized and set forth in MPEP .sctn.1730 II.B.2(a)(C), is incorporated herein by reference in its entirety for all purposes. The

FIELD OF THE INVENTION The invention described herein relates to a novel gene and its encoded protein, termed PC-LECTIN, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express PC-LECTIN, particularly prostate cancers. BACKGROUND OF THE

FIELD OF THE INVENTION The invention described herein relates to a novel gene and its encoded protein, termed PC-LECTIN, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express PC-LECTIN, particularly prostate cancers. BACKGROUND OF THE

FIELD OF THE INVENTION The invention described herein relates to a novel gene and its encoded protein, termed PC-LECTIN, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express PC-LECTIN, particularly prostate cancers. BACKGROUND OF THE

FIELD OF THE INVENTION The invention described herein relates to a novel gene and its encoded protein, termed PC-LECTIN, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express PC-LECTIN, particularly prostate cancers. BACKGROUND OF THE

BACKGROUND OF THE INVENTION Progress in methods to detect and treat cancer has led to increased five-year survival rates. However, cancer mortality rates have not decreased proportionately (Welch, et al. (2000) JAMA 283:2975-2978). Some transformed cells can survive medical treatment and lay dormant

BACKGROUND OF THE INVENTION Progress in methods to detect and treat cancer has led to increased five-year survival rates. However, cancer mortality rates have not decreased proportionately (Welch, et al. (2000) JAMA 283:2975-2978). Some transformed cells can survive medical treatment and lay dormant

TECHNICAL FIELD OF THE INVENTION This invention relates to carbohydrate-binding proteins (lectins) of mammalian tumor cells which specifically recognize and bind to carbohydrate molecules and to methods of isolating these lectins from mammalian tumor cells. BACKGROUND ART The designation "lectin" is

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a novel lectin like protein substance, method of obtaining same and anti-tumor agent comprising the same as an effective ingredient. The substance is produced through a cultivation of an insect cell and more

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a national stage application (under 35 U.S.C. .sctn. 371) of PCT/EP2017/053429, filed Feb. 15, 2017, which claims benefit of European Application No. 16155735.0, filed Feb. 15, 2016, both of which are incorporated herein by reference in

BACKGROUND OF THE INVENTION 1. Field of the Invention The invention relates to a Chaenomeles lagenaria extract and a method for extracting the same, and more particularly, to a Chaenomeles lagenaria extract that is effective in tumor growth inhibition and applicable to blood typing and method for

BACKGROUND OF THE INVENTION 1. Field of Invention This invention relates to a method for diagnosing cancer by qualitative and quantitative determination according to an immuno-serological assay of cancer-related antigens in a body fluid, particularly glycoprotein, glycolipid and glycoantigen

FIELD OF THE INVENTION The invention described herein relates to a novel gene and its encoded protein, termed PC-LECTIN, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express PC-LECTIN, particularly prostate cancers. BACKGROUND OF THE

TECHNICAL FIELD The present invention relates to a method of analyzing diagnostic information pertaining to a benign prostate disease and prostate cancer. The present invention also relates to a method of analyzing diagnostic information based on the blood concentration of mucin-1 having a specific